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Abstract
Haemodialysis patients are at higher risk of developing active tuberculosis (TB) infection. However, tuberculin skin tests (TST) have lim-
itations and the diagnostic usefulness of interferon-c-release assays (IGRAs) remains unclear in immunocompromised hosts including
haemodialysis patients. Haemodialysis patients were enrolled from a dialysis centre in Korea, an intermediate TB-burden country with a
high bacille Calmette–Gue´rin (BCG) vaccination rate. The QuantiFERON-Gold TB In tube test (QFT) and the T-SPOT TB test
(TSPOT) were performed, along with the TST. We stratiﬁed patients to low- and high-risk groups, according to the risk factors for
latent TB. Association between each of the three diagnostic tests and the risk of latent TB was analysed. One hundred and sixty-seven
patients were enrolled. The positive rates for the TST, the QFT and TSPOT were 23.5, 45.9 and 60.4%, respectively. Previous BCG
vaccination increased the TST-positive rate in the low-risk group (OR 4.438), whereas it affected neither QFT nor TSPOT. The positive
QFT rates were 41.2 and 62.5% in the low- and high-risk groups, respectively. The QFT was associated with the high-risk group (OR
2.578), whereas the TST was not. The positive TSPOT rates were 58.9 and 65.7% in the low- and high-risk groups, respectively. The
frequency of indeterminate results was higher for the QFT (12.6%) compared with the TSPOT (4.8%). In conclusion, the IGRAs can be
useful for the diagnosis of latent TB infection in haemodialysis patients.
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Introduction
Tuberculosis (TB) infection is still an important public health
issue worldwide. Both the incidence and mortality of TB
infection are higher in haemodialysis (HD) patients compared
with the general population [1]. Moreover, HD patients have
a higher risk of reactivation of latent TB due to their compro-
mised cell-mediated immunity [2] and dialysis units can be a
source of TB spread [3]. Therefore, it is important to identify
and treat latent TB infection among HD patients to prevent
the reactivation and spread of TB in dialysis units [2]. The
tuberculin skin test (TST) has been used as the standard diag-
nostic tool for latent TB infection. However, its sensitivity is
low in immunocompromised hosts including HD patients [4–
6]. In individuals who have been vaccinated with bacille Cal-
mette–Gue´rin (BCG) the TST has an increased false-positive
rate [7]. Therefore, the TST has potential limitations for the
diagnosis of latent TB infection in HD patients.
Recently, interferon-c-release assays (IGRAs) have been
useful for the diagnosis of latent TB in immunocompetent
hosts [6]. Reports on the IGRAs include the QuantiFERON-
TB test (QFT) and the T-SPOT-TB test (TSPOT) [8]. These
tests are more convenient than the TST, because they are
less invasive and do not require a follow-up visit. In addition,
these tests are not affected by a previous BCG vaccination
and are less inﬂuenced by a non-tuberculosis mycobacterial
infection, because TB-speciﬁc antigens are used [6,8]. Their
sensitivity for active TB infection has been estimated to be
70–90% [6]. However, there is limited information on their
diagnostic usefulness in HD patients. Recently, three groups
reported that the IGRAs were better diagnostic tools
compared with the TST for latent TB infection in HD
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patients, but all studies were performed in low TB-
burden countries [4,9,10]. Therefore, in this study, two IG-
RAs (QFT and TSPOT) were simultaneously compared with
the TST for their diagnostic efﬁcacy for latent TB infection in
Korea, an intermediate TB-burden country.
Patients and Methods
Study population
The study participants were recruited from 1 March to
30 April 2008. They had received HD for at least 3 months
at the Gil Medical Centre, Gachon University of Medicine
and Science. Those patients who had taken empirical anti-TB
medications and patients taking anti-TB medication for active
TB infection were excluded. The study protocols were
approved by the local Institutional Review Board (200804-
01-I033) and all participants gave informed consent. This
study was registered at the International Standard Random-
ized Controlled Trial Number Registry (http://www.con-
trolled-trials.com/ISRCTN52111135).
Clinical data
A history of TB infection and contact with patients who
had active TB was determined by patient report. Patients
who had a microbiologically or radiologically conﬁrmed TB
infection were considered to have a history of TB infection.
A close contact was deﬁned as a household contact or a
work contact, in the same room for > 8 h a day. The
comorbidity and medication history of immunosuppressants
were also noted. Patients who reported BCG vaccination in
the past or had a BCG vaccination scar conﬁrmed by physi-
cians were regarded as patients with a previous BCG vacci-
nation. Standard chest X-rays (CXR) were requested for all
participants and the most current ﬁlm, within 6 months
before the study enrolment, was reviewed for patients who
refused another CXR. All CXR were reviewed by the same
pulmonary radiologist, blind to the patients’ clinical informa-
tion. The CXR ﬁndings were classiﬁed into three catego-
ries: normal, inactive TB lesions and active TB lesions.
Fibronodular lesions in the upper lobe, calciﬁed mediastinal
lymph nodes, pleural thickening and any other lesions con-
sistent with a previous TB infection were regarded as inac-
tive TB lesions [9,11]. In addition, sputum acid fast bacteria
(AFB) staining, sputum TB culture and sputum TB PCR
were performed.
The interferon-c-release assays and the tuberculin skin test
Whole blood was extracted just before dialysis for the two
IFN-c tests. The QFT was performed according to the manu-
facturer’s instructions (Cellestis Ltd., Carnegie, Victoria,
Australia) [12]. The TSPOT was also performed according to
the manufacturer’s instructions (Oxford Immunotec, Oxford,
UK) [9]. Results of each test were classiﬁed as positive, neg-
ative or indeterminate, as previously described [13]. Within
a week after the IGRAs, 2-TU of puriﬁed protein derivative
RT23 (Statens Serum Institute, Copenhagen, Denmark) was
intradermally injected on the volar side of the forearm con-
tralateral to the patient’s vascular access. Two physicians,
blind to the patients’ clinical information, measured the main
diameter of the induration after 48 h independently. The
positive criterion was ‡ 10 mm size of the mean values of
two measurements.
Statistical analysis
The high-risk group for latent TB infection consisted of
patients with a history of close contact with TB patients,
old TB lesions on CXR, or a history of TB infection. The
low-risk group was deﬁned as patients who did not have any
of the three risk factors for latent TB. According to this deﬁ-
nition, association of each of the three diagnostic tests with
the high-risk group was analysed using multiple logistic
regression. Association of a previous BCG vaccination with
the diagnostic tests in the low-risk group was also analysed.
The agreement among test results of the TST, QFT and
TSPOT was assessed using j coefﬁcients. All analyses were
performed using SPSS software (version 12.0; SPSS Inc,
Chicago, IL, USA).
Results
Characteristics of the study population
In total 167 patients were enrolled. Their clinical characteris-
tics are summarized in Table 1. Twenty-one patients (12.6%)
had a history of TB infection and all of them received appro-
priate treatment with anti-TB medication. All patients were
ethnic Koreans and none had either anti-human immunodeﬁ-
ciency virus antibodies or non-mycobacterial tuberculosis
infections. The AFB smear test, TB PCR test and TB culture
test were negative in all subjects. Fourteen patients (8.4%)
had a history of contact with active TB patients and 11
patients among them had a history of close contact (Table 1).
Thirty-eight patients (22.8%) belonged to the high-risk group
for latent TB infection (Table 2).
Overall results of the tuberculin skin test, the
QuantiFERON-TB test and the T-SPOT-TB test
Positive rates of TST, QFT and TSPOT were 23.5, 45.9 and
60.4%, respectively (Table 2). The positive rate of TST was
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still low (34.6%) even at a threshold of 5 mm induration.
The positive rates in all three tests were higher in patients
with a cured TB infection (Table 2). The frequency of
indeterminate results was higher for the QFT (12.6%) com-
pared with the TSPOT (4.8%).
Association of the diagnostic tests with the risk of latent
TB infection
The results of the three diagnostic tests according to the
risk groups of latent TB infection were analysed. The positive
TST rates were similar in the low- and high-risk groups
(23.8% vs. 22.2%). The positive QFT rate increased to 62.5%
in the high-risk group (Table 2). The positive TSPOT rates
were high in both groups (58.9% vs. 65.7%, Table 2). Taken
together, these results suggested that the QFT had a trend
towards an increasing response rate according to the
increase in the risk of latent TB infection, whereas the TST
had a low response rate and the TSPOT had a high response
rate regardless of the risk of latent TB infection. The overall
trends were similar for the data that excluded patients with
cured TB infection (Table 2).
Table 3 shows the results from investigating the association
of the three diagnostic tests with the risk of latent TB infection
using the logistic regression analysis. The QFT was indepen-
dently associated with the high-risk group (adjusted OR 2.578;
95% CI 1.063–6.254; p 0.036, Table 3). However, neither the
TST nor the TSPOT was signiﬁcantly associated with the high-
risk group (Table 3). The overall trends were similar in the
analysis after excluding patients with a cured TB infection,
even though the statistical signiﬁcance decreased (Table S1).
Association of a previous BCG vaccination with the diagnos-
tic tests in the group at low risk of latent TB infection
In order to assess impact of a previous BCG vaccination on
the false-positive rate of the diagnostic tests, the association
of a history of previous BCG vaccination with the diagnostic
test results in the low-risk group was analysed. A history of
previous BCG vaccination increased the risk of the positive
TST rate signiﬁcantly (adjusted OR 4.438; 95% CI 1.154–
17.071, p 0.030, Table 4) and therefore might increase the
false-positive rate in TST. However, neither the QFT nor
the TSPOT was affected by a previous BCG vaccination in
the low-risk group (Table 4).
Agreement among the tuberculin skin test, the QuantiFER-
ON-TB test and the T-SPOT-TB test
Overall, the degree of agreement among the three tests was
poor (TST vs. QFT, j = 0.276; TST vs. TSPOT, j = 0.163;
QFT vs. TSPOT, j = 0.273). The concordance rates
between the TST and both IGRAs were low regardless of
TABLE 1. Clinical characteristics of the study population
Mean ± standard
deviation Range
Age (year) 54.1 ± 14.4 17.0 – 88.0
Duration of haemodialysis (months) 60.8 ± 57.5 3.0 – 336.0
Serum albumin (g/dL) 3.85 ± 0.36 2.25 – 4.65
Number of events
Proportion
of event (%)
Sex (M:F) 71:96 42.5:57.5
Cause of end-stage renal disease
Diabetes mellitus 67 40.1
Hypertension 18 10.8
Glomerulonephritis 12 7.2
Others 11 6.6
Unknown 59 35.3
Diabetes mellitus 80 47.9
History of cancer 12 7.2
Cardiac disease 46 27.5
Cerebrovascular accident 13 7.8
History of TB infection 21 12.6
Pulmonary TB infection 15 –
Extrapulmonary TB infection 6 –
History of contact with TB patients 14 8.4
Inactive TB lesions on chest X-rays 17 10.2
History of BCG
vaccination or BCG scar
111 67.3
Immunosuppressant medication 9 5.4
TABLE 2. Results of the tuberculin
skin tests, the QuantiFERON-TB
tests and the T-SPOT-TB tests
Risk factor
Tuberculin skin test
(‡10 mm) (+)
QuantiFERON-
TB test (+)
T-SPOT-
TB test (+)
Inclusion of patients with a cured
TB infection
Total patients (n = 167) 38 (23.5%) 67 (45.9%) 96 (60.4%)
Low-risk group (n = 129) 30 (23.8%) 47 (41.2%) 75 (58.9%)
High-risk group (n = 38) 8 (22.2%) 20 (62.5%) 23 (65.7%)
Patient with a cured
TB infection (n = 21)
6 (30%) 11 (68.8%) 15 (71.4%)
Exclusion of patients with
a cured TB infection
Total patients (n = 146) 32 (22.5%) 56 (43.1%) 81 (58.7%)
Low-risk group (n = 129) 30 (23.8%) 47 (41.2%) 75 (58.9%)
High-risk group (n = 17) 2 (12.5%) 9 (56.3%) 8 (57.1%)
Results were expressed by both number and proportion (in parentheses) of the positive response.
TB, Mycobacterium tuberculosis.
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the risk of latent TB infection due to the poor sensitivity of
the TST in the HD patients. However, good agreement was
observed between the QFT and the TSPOT in patients with
a cured TB infection (j = 0.538, Table 5). Thirty-eight
patients (27.3%) gave negative results for both the QFT and
the TSPOT and 49 patients (35.3%) gave positive results for
both tests, whereas 52 patients (37.4%) gave discordant
results (Table 5).
Discussion
Latent TB infection was studied among four different risk
groups in the general Korean population [14]. In the low-risk
group, the positive response rates of the TST and the QFT
were 51% and 4%, respectively. In the close contact group
the positive response rates increased to 71% and 44%,
respectively. Consistent with these results, the QFT results
were proportional to the risk of latent TB infection in our
data. However, the positive QFT rate in the low-risk group
in our study was close to the value in the close contact
group in the general population (41.2% vs. 44%). This result
can be attributed to the fact that HD patients belong to a
high-risk group compared with the general population,
regardless of additional risk factors [1].
The positive TST rate was much lower in the HD
patients, even in Korea with a high BCG vaccination rate and
an intermediate TB burden [15]. A previous BCG vaccination
TABLE 3. Association of the diag-
nostic tests with the high-risk
group of latent TB infection
Variable
Univariable logistic
regression analysis
Multivariable logistic
regression analysis
OR (95% CI) p value Adjusted OR (95% CI) p value
Age 0.977 (0.950–1.006) 0.123
Sex 0.725 (0.325–1.617) 0.432
Diabetes mellitus 0.532 (0.233–1.215) 0.134
History of cancer 0.421 (0.051–3.463) 0.421
Cardiac disease 1.117 (0.464–2.687) 0.805
Previous BCG vaccination 0.551 (0.242–1.256) 0.156
Immunosuppressant 1.143 (0.225–5.805) 0.872
Serum albumin 0.628 (0.226–1.747) 0.373
Tuberculin skin test 1.129 (0.454–2.806) 0.795 1.251 (0.458–3.417)a 0.663
QuantiFERON-TB test 2.433 (1.072–5.522) 0.033 2.578 (1.063–6.254)a 0.036
T-SPOT-TB test 1.125 (0.498–2.543) 0.777 1.155 (0.481–2.773)a 0.747
TB, Mycobacterium tuberculosis; BCG, bacille Calmette–Gue´rin.
aAdjusted for age, sex, diabetes mellitus, history of cancer, cardiac disease, previous BCG vaccination,
immunosuppressant and albumin.
TABLE 4. Association of a previous
BCG vaccination with the diagnos-
tic tests in the low-risk group of
latent TB infection
Variable
Univariable logistic
regression analysis
Multivariable logistic
regression analysis
OR (95% CI) p value Adjusted OR (95% CI) p value
Tuberculin skin test
Previous BCG vaccination 4.667 (1.293–16.848) 0.018 4.438 (1.154–17.071)a 0.030
QuantiFERON-TB test
Previous BCG vaccination 0.976 (0.418–2.279) 0.954 1.068 (0.422–2.703)a 0.890
T-SPOT-TB test
Previous BCG vaccination 1.464 (0.626-3.426) 0.380 1.332 (0.542-3.277)a 0.532
TB, Mycobacterium tuberculosis; BCG, bacille Calmette–Gue´rin.
aAdjusted for age, sex, diabetes mellitus, history of cancer, cardiac disease, immunosuppressant and albumin.
TABLE 5. Comparison between
the QuantiFERON-TB test and the
T-SPOT-TB test QuantiFERON-TB test
T-SPOT-TB test
j coefﬁcientNegative result Positive result
Total patients Negative result 38 (27.3%) 39 (28.1%) 0.273
Positive result 13 (9.4%) 49 (35.3%)
Patients with a cured TB infection Negative result 3 (18.8%) 2 (12.5%) 0.538
Positive result 1 (6.3%) 10 (62.5%)
TB, Mycobacterium tuberculosis.
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increased the positive TST rate in the group at low risk of
latent TB infection, a surrogate marker for the false-positive
rate. Therefore, both the low positive TST rate and the pos-
sibility of false-positive results diminish the usefulness of the
TST for the diagnosis of latent TB infection in Korean HD
patients. However, a previous BCG vaccination did not inﬂu-
ence the results of the QFT or the TSPOT.
There are several previous studies on IGRAs in HD patients
[4,9,10]. In the Canadian study, the positive TSPOT rate was
35.5% [9]. In the American study, the positive rates of the
QFT and the TSPOT were 22% and 28%, respectively [10].
The positive rates of both the QFT and the TSPOT in these
studies were lower than the 45.9% (QFT) and 60.4% (TSPOT)
found in this study. These results may reﬂect the relative TB
burden in each country. Taken together, these data suggested
that the IGRA is also effective in detecting latent TB infection
in HD patients in countries with an intermediate to high TB
burden.
Currently, there is no established standard diagnostic
method for latent TB infection. Therefore, we stratiﬁed
patients to the low- and high-risk groups for latent TB infection
instead of deﬁning latent TB itself, in order to analyse the asso-
ciation between the three diagnostic tests and the risk of latent
TB infection. The QFT results were signiﬁcantly associated with
the high-risk group. In contrast, the positive TSPOT rates were
high even in the low-risk group. These results suggest that the
TSPOT could be sensitive enough to detect hidden latent TB
infection in the low-risk group [6]. Considering both low sensi-
tivity and low speciﬁcity of TST in HD patients, we would rec-
ommend the use of IGRAs as the screening test in HD patients,
including renal transplantation candidates before transplanta-
tion. Long-term follow-up studies to assess the predictive ability
of the IGRAs for future active TB infection are needed in order
to conﬁrm their validity in these patients. There was no signiﬁ-
cant risk factor for the discordant results between the QFT and
the TSPOT, perhaps due to the low number of cases. Interest-
ingly, most of the discordant results had a pattern of a negative
result for the QFT with a positive result for the TSPOT, consis-
tent with a higher sensitivity of the TSPOT [6,16]. Further,
large-scale studies are needed to reveal the causes of the dis-
cordant results. The QFT gave a higher rate of indeterminate
results than the TSPOT, consistent with the ﬁndings in previous
reports [9,12,17].
The patients with a history of cured TB infection were
not candidates for anti-TB medications for latent TB infec-
tion, because the risk of progression to active TB infection is
low in this group [18,19]. However, this group can give a
positive response on the IGRAs [8,20]. On analysis of the
data, omitting those from the cured TB patients, the overall
trends were found to be similar.
In summary, the TST was not useful for the diagnosis of
latent TB infection in Korean HD patients. Both the QFT
and the TSPOT were more sensitive compared with the TST
and were not affected by a previous BCG vaccination. In
conclusion, the IGRAs can be useful for diagnosis of latent
TB infection, a common and important problem in HD
patients.
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